尖锐湿疣患者病损中VEGF、COX-2及MVD的作用探讨  

VEGF,COX-2 and MVD in Lesions of Patients with Condyloma Acuminatum

作　　者：刘彤[1] 张洪辉[1] 

机构地区：[1]西安交通大学医学院第一附属医院皮肤科,西安710061

出　　处：《四川大学学报（医学版）》2009年第2期263-267,共5页Journal of Sichuan University(Medical Sciences)

摘　　要：目的探讨血管内皮生长因子(VEGF)、环氧合酶2(COX-2)在尖锐湿疣(CA)发病和发展中的作用及其相互关系。方法采用免疫组化SP法检测61例CA患者病损中VEGF、COX-2的表达和微血管密度(MVD),并以17例健康男性皮肤作为对照。结果CA组VEGF、COX-2表达阳性率和范围强度积分均高于对照组(P<0.05),且CA病损中VEGF与COX-2表达呈显著正相关(r=0.749,P<0.05)。随CA病损直径增大、数目增多,VEGF、COX-2表达范围强度积分也就增高(P<0.05),而不同病程间两者的表达阳性率和范围强度积分差异无统计学意义(P>0.05)。CA病损的MVD较对照增高(P<0.05)。CA病损中VEGF、COX-2表达阳性者的MVD均高于阴性者(P<0.05),且两者均与MVD呈正相关(r=0.348,0.327,P<0.05)。结论VEGF、COX-2可促使CA病损出现异常的血管新生和细胞增殖,促进疣体增大、数目增多和病情进展,两者在CA发生、发展中有协同作用。Objective To determine the roles of vascular endothelial growth factor （VEGF） and cyclooxygenase-2 （COX-2） in the occurrence and development of condyloma acuminatum （CA）. Methods The VEGF, COX-2, and microvascular density （MVD） in the lesions of 61 CA patients were detected with immunohistochemical SP method. Seventeen skin tissues from healthy men served as controls. Results The CA patients had greater positive rate and field-strength scores of VEGF and COX-2 than the controls （P〈0. 05）. VEGF positively correlated with COX-2 in the CA lesions （r=0. 749, P〈0.05）. With the increase of number and diameters of CA lesions, the field-strength scores of VEGF and COX-2 increased （P〈0.05）. The positive rates and field-strength scores did not change with the courses of the CA disease （P〉0.05）. The CA lesions also had greater MVD than the controls （P〈0.05）. The CA lesions with positive VEGF and COX-2 had greater MVD than those with negative VEGF and COX-2 （P〈0.05）. Both VEGF and COX-2 were positively correlated with MVD （r= 0. 348 and 0. 327 respectively, P〈0.05）. Conclusion VEGF and COX-2 promote the abnormal angiogenesis and the cell proliferation in CA lesions, which accelerate the progress of wart lesions. The two factors have synergistic effect on the occurrence and development of CA.

关 键 词：尖锐湿疣 血管内皮生长因子 环氧合酶-2 微血管密度 免疫组化染色 

分 类 号：R752.53[医药卫生—皮肤病学与性病学]